30 Jun 2016
Lonza Acquires Triangle Research Labs, a Hepatocyte Provider Based in North Carolina (USA)

Basel, Switzerland, 30 June 2016 – Lonza announced today that it recently acquired Triangle Research Labs (TRL) from PBM Capital Group. TRL is a fast-growing hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications. Triangle Research Labs has facilities based in Research Triangle Park, North Carolina (USA).

“By adding TRL with its highly qualified colleagues to our global business, Lonza further strengthens its position as a worldwide leader in cell discovery. Integrating this business into its primary cell portfolio lays the basis for new product offerings and the entry into new strategic markets,” said Teun van der Heide, Vice President, Head of Bioscience Solutions for Lonza. “The acquisition is in line with Lonza's strategy to continue to develop its life-science platform and to expand its global cell-biology portfolio.”

Triangle Research Labs was established in 2012 and has quickly gained a reputation for high-quality products and a unique ability to understand each customer's specific needs. This combination makes TRL a great asset to Lonza's mission of serving customers in the bioresearch space through a culture of trust and care.

Matthew Sherman, Managing Director TRL, which is now part of Lonza, added: “TRL couldn't have hoped for a better partner than Lonza. It is a natural fit; we share the same vision and our products complement each other. Lonza's expertise in cell systems and regard for high-quality products will ensure a smooth transition as we become part of the larger company. Both parties are dedicated to increasing the size and scale of the TRL business and our products. Increased focus on R&D will help propel this business to a market leader in emerging technologies. We believe this acquisition is in the best interest of our customers and employees.”

The TRL team is well versed in the ADME/Toxicology field of drug discovery and development. TRL offers fresh and cryopreserved hepatocytes and non-parenchymal hepatic cells from a variety of species, as well as supporting media and culture systems.